Enanta Pharmaceuticals (NASDAQ:ENTA) Rating Increased to Buy at Jefferies Financial Group

Key Points

• Jefferies Financial Group upgraded Enanta Pharmaceuticals from a "hold" to a "buy" rating, with a target price of $20.00, indicating a potential upside of 83.55%.
• Other analysts have varying opinions, with Westpark Capital raising its price target to $28.00 while Evercore ISI lowered its target to $12.00, reflecting a mix of confidence in the stock's future.
• Enanta Pharmaceuticals recently reported better-than-expected earnings, with revenues of $18.31 million exceeding analyst estimates, but they continue to show significant negative margins.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) was upgraded by research analysts at Jefferies Financial Group from a "hold" rating to a "buy" rating in a research report issued to clients and investors on Wednesday,Briefing.com Automated Import reports. The firm presently has a $20.00 target price on the biotechnology company's stock. Jefferies Financial Group's price objective suggests a potential upside of 83.55% from the company's current price.

ENTA has been the topic of several other reports. Westpark Capital boosted their price target on Enanta Pharmaceuticals from $24.00 to $28.00 and gave the company a "buy" rating in a research note on Tuesday. Evercore ISI decreased their price objective on Enanta Pharmaceuticals from $20.00 to $12.00 and set an "outperform" rating for the company in a report on Monday, September 15th. JMP Securities boosted their price objective on Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a "market outperform" rating in a report on Tuesday, August 12th. Wall Street Zen upgraded Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a report on Sunday, June 22nd. Finally, HC Wainwright started coverage on Enanta Pharmaceuticals in a report on Monday, July 28th. They set a "buy" rating and a $20.00 price objective for the company. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, Enanta Pharmaceuticals currently has a consensus rating of "Buy" and a consensus price target of $20.83.

Enanta Pharmaceuticals Stock Performance

Shares of NASDAQ:ENTA traded down $1.07 during midday trading on Wednesday, hitting $10.90. 2,461,565 shares of the stock were exchanged, compared to its average volume of 386,893. The stock has a market capitalization of $232.96 million, a price-to-earnings ratio of -2.52 and a beta of 0.84. The business's 50-day moving average price is $8.19 and its 200 day moving average price is $6.91. Enanta Pharmaceuticals has a 12 month low of $4.09 and a 12 month high of $15.34.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last posted its quarterly earnings data on Monday, August 11th. The biotechnology company reported ($0.85) EPS for the quarter, topping analysts' consensus estimates of ($1.25) by $0.40. The company had revenue of $18.31 million for the quarter, compared to analyst estimates of $16.21 million. Enanta Pharmaceuticals had a negative return on equity of 89.02% and a negative net margin of 141.98%. As a group, sell-side analysts expect that Enanta Pharmaceuticals will post -4.65 EPS for the current year.

Institutional Trading of Enanta Pharmaceuticals

Institutional investors have recently added to or reduced their stakes in the stock. US Bancorp DE purchased a new stake in Enanta Pharmaceuticals during the 1st quarter worth about $36,000. GAMMA Investing LLC purchased a new stake in Enanta Pharmaceuticals during the 1st quarter worth about $40,000. Farther Finance Advisors LLC lifted its holdings in Enanta Pharmaceuticals by 11,558.0% during the 2nd quarter. Farther Finance Advisors LLC now owns 5,829 shares of the biotechnology company's stock worth $44,000 after purchasing an additional 5,779 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in shares of Enanta Pharmaceuticals in the 4th quarter valued at about $66,000. Finally, MetLife Investment Management LLC purchased a new stake in shares of Enanta Pharmaceuticals in the 1st quarter valued at about $72,000. Hedge funds and other institutional investors own 94.99% of the company's stock.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.